What is the ticker symbol for InMed Pharmaceuticals?

InMed Pharmaceuticals trades under the ticker INM on NASDAQ.

What sector does InMed Pharmaceuticals operate in?

InMed Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze INM in a portfolio?

PortView shows INM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

InMed Pharmaceuticals (INM) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$1.61+1.26%

1-year price historyRange $0.62 – $2.00

52-week range$1.61

$0.58$2.33

Track INM in your portfolio for free · Portfolio tracker

What InMed Pharmaceuticals does

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

Key metrics

Market cap

$8.84M

P/E (TTM)

-0.52

EPS (TTM)

$-3.07

Beta

0.93

Dividend yield

2.19%

Revenue / share

$154.84

50-day avg

$1.38

200-day avg

$1.20

52-week high

$2.33

52-week low

$0.58

CEO

Eric A. Adams Chem.

ETFs linked to INM

Broad-market and Healthcare sector ETFs an investor holding InMed Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how INM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze INM in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for InMed Pharmaceuticals?: InMed Pharmaceuticals trades under the ticker INM on NASDAQ.
Which exchange is INM listed on?: INM is listed on NASDAQ.
What sector does InMed Pharmaceuticals operate in?: InMed Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze INM in a portfolio?: PortView shows INM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.